![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection STOCKHOLM, Sweden, June 12 2024. Karolinska...
Karolinska Development invests in BOOST Pharma, expanding its portfolio STOCKHOLM, SWEDEN – May 28, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has...
Karolinska Development’s Annual General Meeting 2024 STOCKHOLM, SWEDEN – May 16, 2024. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held the Annual General Meeting...
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC STOCKHOLM, SWEDEN – May 8, 2024. Karolinska Development AB (Nasdaq...
Interim Report - January-March 2024 STOCKHOLM – 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is...
Notice of Annual General Meeting in Karolinska Development AB (publ) The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are...
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC STOCKHOLM, SWEDEN – March 22, 2024. Karolinska...
Karolinska Development Annual Report 2023 published STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2023...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 6.5 | 6.5 | 6.5 | 36429 | 6.5 | DE |
4 | 0 | 0 | 6.5 | 6.5 | 6.5 | 36429 | 6.5 | DE |
12 | 0 | 0 | 6.5 | 6.5 | 6.5 | 36429 | 6.5 | DE |
26 | 0 | 0 | 6.5 | 6.5 | 6.5 | 13299 | 6.5 | DE |
52 | 0 | 0 | 6.5 | 6.5 | 6.5 | 5681 | 6.5 | DE |
156 | 0 | 0 | 6.5 | 6.5 | 6.5 | 9127 | 6.5 | DE |
260 | 0 | 0 | 6.5 | 6.5 | 6.5 | 9505 | 6.5 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions